Search details
1.
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
Lancet Oncol
; 2024 Jun 05.
Article
in English
| MEDLINE | ID: mdl-38851207
2.
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 990-1000, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35767205
3.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.
J Natl Compr Canc Netw
; 20(3): 224-234, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35276673
4.
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Lancet Oncol
; 22(6): 883-892, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33989559
5.
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Cancer
; 126(14): 3237-3243, 2020 07 15.
Article
in English
| MEDLINE | ID: mdl-32365226
6.
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Cancer
; 126(10): 2146-2152, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-32073648
7.
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(7): 873-898, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32634781
8.
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Lancet Oncol
; 20(9): 1295-1305, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31351869
9.
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Lancet Oncol
; 19(8): 1082-1093, 2018 08.
Article
in English
| MEDLINE | ID: mdl-30001987
10.
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.
J Natl Compr Canc Netw
; 16(5): 479-490, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29752322
11.
Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil.
Cancer
; 123(23): 4594-4607, 2017 Dec 01.
Article
in English
| MEDLINE | ID: mdl-28881377
12.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Lancet
; 388(10043): 488-97, 2016 Jul 30.
Article
in English
| MEDLINE | ID: mdl-27291997
13.
NCCN Guidelines Insights: Bone Cancer, Version 2.2017.
J Natl Compr Canc Netw
; 15(2): 155-167, 2017 02.
Article
in English
| MEDLINE | ID: mdl-28188186
14.
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
J Natl Compr Canc Netw
; 15(6): 761-770, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28596256
15.
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
BMC Cancer
; 16: 19, 2016 Jan 14.
Article
in English
| MEDLINE | ID: mdl-26768732
16.
Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.
Cancer
; 120(24): 3994-4002, 2014 Dec 15.
Article
in English
| MEDLINE | ID: mdl-25143048
17.
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Lancet Oncol
; 14(3): 257-64, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23414589
18.
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 14(4): 371-82, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23477833
19.
Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Clin Cancer Res
; 30(9): 1934-1944, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38372707
20.
Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.
J Cancer Surviv
; 2024 Apr 17.
Article
in English
| MEDLINE | ID: mdl-38630333